Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

J Allergy Clin Immunol. 2017 Sep;140(3):875-879.e1. doi: 10.1016/j.jaci.2017.03.013. Epub 2017 Apr 4.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors*
  • Aged
  • Allergens / immunology
  • Anti-Allergic Agents / therapeutic use*
  • Basophils / drug effects*
  • Basophils / immunology
  • Humans
  • Lymphoproliferative Disorders / drug therapy
  • Lymphoproliferative Disorders / immunology
  • Male
  • Middle Aged
  • Piperidines
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Skin Tests

Substances

  • Allergens
  • Anti-Allergic Agents
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Agammaglobulinaemia Tyrosine Kinase
  • Adenine